Alexion Pharmaceuticals Inc logo

ALXN - Alexion Pharmaceuticals Inc Share Price

$156.7 0.1  0.0%

Last Trade - 9:00pm

Sector
Healthcare
Size
Large Cap
Market Cap £25.03bn
Enterprise Value £25.25bn
Revenue £4.28bn
Position in Universe 344th / 6543
Bullish
Bearish
Unlock ALXN Revenue
Momentum
Relative Strength (%)
1m -3.63%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -2.11%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
2,234 2,604 3,084 3,551 4,131 4,991 5,988 6,539 +17.4%
+148.7 -73.4 +123.5 +32.6 +100.9 +97.0 +13.1 +6.93
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AlexionPharmaceuticals, Inc. revenues increased 24% to $4.48B. Netincome decreased 96% to $67.6M. Revenues reflect Solirissegment increase from $990.5M to $3.04B, ULTOMIRIS segmentincrease from $89.9M to $763.2M. Net income was offset byChange in fair value of contingent consi increase from$7.2M to $45M (expense), Interest rate swap contractsdecrease from $12.5M (income) to $14.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ALXN
Graphical History

Revenue

ALXN Revenue Unlock ALXN Revenue

Net Income

ALXN Net Income Unlock ALXN Revenue

Normalised EPS

ALXN Normalised EPS Unlock ALXN Revenue

PE Ratio Range

ALXN PE Ratio Range Unlock ALXN Revenue

Dividend Yield Range

ALXN Dividend Yield Range Unlock ALXN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALXN EPS Forecasts Unlock ALXN Revenue
Profile Summary

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 28, 1992
Public Since February 1, 1996
No. of Shareholders: 87
No. of Employees: 3,082
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 218,720,567
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALXN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALXN
Upcoming Events for ALXN
Thursday 28th January, 2021 Estimate
Q4 2020 Alexion Pharmaceuticals Inc Earnings Release
Tuesday 4th May, 2021 Estimate
Q1 2021 Alexion Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Alexion Pharmaceuticals Inc
What is the Alexion Pharmaceuticals Inc share price?

As of 9:00pm, shares in Alexion Pharmaceuticals Inc are trading at $156.7, giving the company a market capitalisation of £25.03bn. This share price information is delayed by 15 minutes.

How has the Alexion Pharmaceuticals Inc share price performed this year?

Shares in Alexion Pharmaceuticals Inc are currently trading at $156.7 and the price has moved by 39.21% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Alexion Pharmaceuticals Inc price has moved by 21.19% over the past year.

What are the analyst and broker recommendations for Alexion Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Alexion Pharmaceuticals Inc, there are there are currently 1 "buy" , 14 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Alexion Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Alexion Pharmaceuticals Inc next release its financial results?

Alexion Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Alexion Pharmaceuticals Inc dividend yield?

Alexion Pharmaceuticals Inc does not currently pay a dividend.

Does Alexion Pharmaceuticals Inc pay a dividend?

Alexion Pharmaceuticals Inc does not currently pay a dividend.

When does Alexion Pharmaceuticals Inc next pay dividends?

Alexion Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Alexion Pharmaceuticals Inc shares?

To buy shares in Alexion Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Alexion Pharmaceuticals Inc?

Shares in Alexion Pharmaceuticals Inc are currently trading at $156.7, giving the company a market capitalisation of £25.03bn.

Where are Alexion Pharmaceuticals Inc shares listed? Where are Alexion Pharmaceuticals Inc shares listed?

Here are the trading details for Alexion Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALXN
What kind of share is Alexion Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Alexion Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Alexion Pharmaceuticals Inc share price forecast 2021?

Shares in Alexion Pharmaceuticals Inc are currently priced at $156.7. At that level they are trading at 10.85% discount to the analyst consensus target price of 0.00.

Analysts covering Alexion Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of 12.116 for the next financial year.

How can I tell whether the Alexion Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alexion Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 22.4%. At the current price of $156.7, shares in Alexion Pharmaceuticals Inc are trading at 34.89% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Alexion Pharmaceuticals Inc PE Ratio?

The Alexion Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 months is 14.61. The shares are currently trading at $156.7.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Alexion Pharmaceuticals Inc?

Alexion Pharmaceuticals Inc's management team is headed by:

John Mollen - IND
David Brennan - CHM
Christopher Coughlin - IND
Felix Baker - IND
Ludwig Hantson - CEO
Brian Goff - EVP
Paul Friedman - IND
Deborah Dunsire - IND
Ellen Chiniara - EVP
Indrani Franchini - EVP
John Orloff - EVP
Aradhana Sarin - CFO
Tanisha Carino - EVP
Uzair Qadeer - OTH
Becky Lillie - OTH
Who are the major shareholders of Alexion Pharmaceuticals Inc?

Here are the top five shareholders of Alexion Pharmaceuticals Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.07% (19.8m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.68% (12.4m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 5.09% (11.1m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 4.01% (8.76m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 3.86% (8.45m shares)
Similar to ALXN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.